ketanserin has been researched along with Cerebrovascular Disorders in 6 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "(S)-Emopamil has a less potent calcium antagonistic effect (EC50 = 270 nmol/l) on the aorta than verapamil and gallopamil (EC50 = 35 and 14 nmol/l, respectively)." | 5.28 | (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile. ( Hofmann, HP; Raschack, M; Unger, L, 1989) |
| "To determine whether ketanserin, an antagonist at the serotonin receptor, prevents important vascular events such as death, myocardial infarction, major stroke, and amputation of a leg in patients with claudication." | 5.06 | Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. ( , 1989) |
| "(S)-Emopamil has a less potent calcium antagonistic effect (EC50 = 270 nmol/l) on the aorta than verapamil and gallopamil (EC50 = 35 and 14 nmol/l, respectively)." | 1.28 | (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile. ( Hofmann, HP; Raschack, M; Unger, L, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lüscher, TF | 1 |
| Tanner, FC | 1 |
| Bühler, FR | 1 |
| Hofmann, HP | 1 |
| Raschack, M | 1 |
| Unger, L | 1 |
| Birkenhäger, WH | 1 |
| de Leeuw, PW | 1 |
| Minami, M | 1 |
| Hamaue, N | 1 |
| Togashi, H | 1 |
| Matsumoto, M | 1 |
| Yoshioka, M | 1 |
| Saito, H | 1 |
| David, JL | 1 |
2 reviews available for ketanserin and Cerebrovascular Disorders
| Article | Year |
|---|---|
[Serotonin and cardiovascular diseases. Pathophysiology and significance of serotonin antagonists].
Topics: Aged; Animals; Arterial Occlusive Diseases; Blood Platelets; Cardiovascular Diseases; Cerebrovascula | 1992 |
Treatment of the elderly hypertensive: a clinical perspective.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Calcium Channel Blockers; Cerebrovascular Diso | 1988 |
1 trial available for ketanserin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.
Topics: Adult; Amputation, Surgical; Arteriosclerosis; Cardiovascular Diseases; Cause of Death; Cerebrovascu | 1989 |
3 other studies available for ketanserin and Cerebrovascular Disorders
| Article | Year |
|---|---|
(S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile.
Topics: Animals; Binding, Competitive; Calcium Channel Blockers; Cerebrovascular Disorders; Female; Guinea P | 1989 |
Effects of long term oral administration of ketanserin and trichlormethiazide on blood pressure in stroke-prone spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Blood Pressure; Cerebrovascular Disorders; Hypertension; Ketanserin; | 1988 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |